Pharming Group N.V.

NASDAQ:PHAR

Biotechnology

Healthcare
$12.48 +2.19%

+$0.28 today

Market cap
$882.43M
Beta
0.10
P/E (TTM)
77.0
EPS (TTM)
$0.02
52W Low $9.54High $21.34

Volume 0.01M

Average 0.01M

PHAR Other Working Capital

Cash effect of changes in other operating assets and liabilities.

Pharming Group N.V.NASDAQ: PHAR

Other Working Capital · Q1 FY2026 · quarter ended Mar 2026

Other working capital dips below year-ago levels

Q1 FY2026 other working capital of $513.86K (cash outflow) fell 82.2% year over year, behind the +115.4% change in trailing-twelve-month other working capital. Over 3 fiscal years it compounded at -54.0% a year.

Context

  • Other working capital amounted to 0.3% of revenue in FY2025, down 0.6 pp from a year earlier.
  • Other working capital increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -82.2% toward the trailing-twelve-month pace of +115.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$513.86K-143.2% QoQ
Last fiscal yearDec 2025
$1.19M+141.3% YoY
LTMMar 2026
$1.54M+115.4% YoY
Other Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-82.2%——
1 year+141.3%——
3-year CAGR-54.0%——
5-year CAGR——
10-year CAGR——

Other Working Capital history

USD · from the cash flow

Latest · FY2025
1.19M USD
Year-over-year change
+141.3%

Other Working Capital vs competitors

How PHAR compares with its peers on the latest reported figures

  • Peers report in different currencies, so other working capital is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +115.4% is the 3rd highest of 9, against a peer median of +27.2%.
  • Other working capital amounts to 0.4% of revenue for PHAR, versus a peer median of 65.2%.
PHAR Competitors
Other Working Capital for PHAR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$62.68M USD+262.6%+13.9%6.5%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$59.94M USD+41.2%+18.3%90.7%
BCRXBioCryst Pharmaceuticals, Inc.LTM Jun 2026$42.33M USD+4.2%+204.8%4.5%
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026$23.06M USD-64.0%+134.7%0.0%
STOKStoke Therapeutics, Inc.LTM Mar 2026$20.91M USD+15.2%—65.2%
PRQRProQR Therapeutics N.V.LTM Mar 2026€10.48M EUR-2.6%+49.7%78.0%
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$9.99M USD+435.9%+32.1%—
PHVSPharvaris N.V.LTM Sep 2026€8.94M EUR+39.2%-0.4%—
SLNSilence Therapeutics plcLTM Mar 2026$8.34M USD——905.3%
PHARPharming Group N.V.LTM Mar 2026$1.54M USD+115.4%-54.0%0.4%
Peer median (excluding PHAR) —+27.2%+32.1%65.2%

Competitors are the stored peer set for PHAR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income26.16M14.99M(12.01M)(8.79M)2.86M
Depreciation & Amortization22.23M13.19M15.93M16.64M0
Deferred Income Tax00000
Stock-Based Compensation10.27M6.39M9.25M11.65M0
Change in Working Capital(5.62M)(387K)(16.96M)(10.43M)14.4M
Accounts Receivables6.71M2.36M(18.54M)(7.02M)(3.36M)
Inventory(6.98M)(15.02M)(14.43M)(520.85K)(1.29M)
Accounts Payables000017.87M
Other Working Capital(5.36M)12.27M16.01M(2.88M)1.19M
Other Non-Cash Items(10.14M)(11.72M)(13.51M)(10.92M)32.8M
Operating Cash Flow42.9M22.46M(17.3M)(1.86M)50.07M
Capital Expenditures(18.95M)(1.98M)(1.46M)(824.25K)(751.09K)
Acquisitions (Net)07.3M00(65.53M)
Purchases of Investments(5.2M)0(382.01M)(294.4M)0
Sales of Investments00232.81M327.97M0
Other Investing Activities0021.28M084.72M
Investing Cash Flow(24.15M)5.32M(129.39M)32.74M18.43M
Debt Repayment(3.65M)(3.31M)(4.04M)(35.61M)0
Common Stock Issued5.35M2.28M0019.87M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(33.39M)(3.95M)3M(19.67K)(5.39M)
Financing Cash Flow(31.68M)(4.98M)(1.04M)(35.63M)14.48M
Effect of Forex Changes(2.07M)(7.38M)2.13M(2.29M)8.12M
Net Change in Cash(15M)15.42M(145.6M)(7.04M)91.09M
Free Cash Flow23.95M20.48M(18.77M)(2.68M)49.31M

Pharming Group N.V.

NASDAQ:PHAR

Intrinsic Alpha fair value

Locked

Current Price

$12.48

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.